• Highly differentiated vaccine candidate with potentially compelling immunogenicity owing to its VLP structure
  • Phase 3 study ongoing with results expected in the second half of 2023

CHIKV VLP is a virus-like particle (VLP)-based vaccine candidate in Phase 3 clinical development for active immunization against chikungunya disease.  

The Phase 3 development program for CHIKV VLP consists of two studies. One is a multi-center, randomized, double blind, placebo-controlled study evaluating the safety and immunogenicity of the CHIKV VLP vaccine candidate in healthy individuals aged 12 to 64 and aims to compare clinically relevant difference in immune response rate between the candidate vaccine and placebo. It also aims to demonstrate the consistency of the chikungunya virus serum neutralizing antibody response across three manufactured vaccine candidate lots. The study has completed enrollment of 3,150 participants. The second study has enrolled 400 adults ≥65 years of age and is also evaluating the safety and immunogenicity of the CHIKV VLP vaccine. Results from both studies are anticipated in the second half of 2023.

CHIKV VLP has received Breakthrough Therapy designation and Fast Track designation from the FDA, and PRIME designation from EMA.

Chikungunya virus is spread to people by infected mosquitoes. Symptoms include fever, joint pain, headache, muscle pain, joint swelling or rash, with some symptoms lasting months or even years. The geographic distribution of chikungunya has expanded to more than 100 countries and territories worldwide. There is currently no licensed vaccine to prevent chikungunya virus disease.